Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病或者更安全的T2DM，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺，由阿司利康公司开发的长效的口服非甾体结构的抗雄激物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给旧性腰椎间盘突出症(LDH)的近远期效果并探讨其机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的口体结构的抗雄激药物，1995年在英国首。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病或者更安全的T2DM，吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给陈旧性腰椎间盘突出症(LDH)的近远期效果并探讨其理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全的T2DM治疗药，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：治疗药，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给药治疗陈旧性盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿者更安全的T2DM治疗，托吡酯给人们带来了新的希望。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗，最早由阿司利康公司开发的长效的口服非甾体结构的抗雄激物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目的观察推拿六法加硬膜外给治疗陈旧腰椎间盘突出症(LDH)的近远期效果并探讨其治疗机理。

Topiramate raises new hope as an antidiabetic agent or a potential new chemotype with a better safety profile for the treatment of T2DM.

作为一种抗糖尿病药或者更安全T2DM治疗药，托吡酯给人们带来了新。

Prostate drug, It is developed by AstraZenca Internatioal,and it is the first antiandrogen non-corticosteroids drug for long-acting oral medication and firstly go on the market in 1995 in UK.

8 用途Usage：前列腺治疗药，最早由阿司利康公司开发长效口服非甾体结构抗雄激药物，1995年在英国首次上市。

Objective To observe the near future curative effect and that of the distant future on LDH with the treatment of naprapathy six methods and epidrual administration of drugs.

目观察推拿六法加硬膜外给药治疗陈旧性腰椎间盘突(LDH)近远期效果并探讨其治疗机理。